Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
Aclarion (Nasdaq: ACON) announced its participation in the 2025 Spine Summit, where Dr. Nicholas Theodore will showcase the company's NOCISCAN technology. NOCISCAN is a pioneering SaaS platform that combines MR Spectroscopy with augmented intelligence to help physicians identify the location of chronic low back pain.
Dr. Theodore, who serves as Professor at Johns Hopkins University School of Medicine and holds multiple director positions, will present 'NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support' on February 21, 2025. The technology is particularly significant given that approximately 266 million people worldwide suffer from degenerative spine disease and low back pain.
NOCISCAN is the first evidence-supported platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine by objectively quantifying chemical biomarkers associated with disc pain.
Aclarion (Nasdaq: ACON) ha annunciato la sua partecipazione al 2025 Spine Summit, dove il Dr. Nicholas Theodore presenterà la tecnologia NOCISCAN dell'azienda. NOCISCAN è una piattaforma SaaS innovativa che combina la spettroscopia MR con intelligenza aumentata per aiutare i medici a identificare la posizione del dolore lombare cronico.
Il Dr. Theodore, che è Professore presso la Johns Hopkins University School of Medicine e ricopre diverse posizioni dirigenziali, presenterà 'NOCISCAN, Intelligenza Aumentata e Supporto Decisionale per il Dolore Lombare' il 21 febbraio 2025. Questa tecnologia è particolarmente significativa considerando che circa 266 milioni di persone nel mondo soffrono di malattie degenerative della colonna vertebrale e dolore lombare.
NOCISCAN è la prima piattaforma supportata da evidenze che aiuta i medici a distinguere in modo non invasivo tra dischi dolorosi e non dolorosi nella colonna lombare, quantificando oggettivamente i biomarcatori chimici associati al dolore discale.
Aclarion (Nasdaq: ACON) anunció su participación en el 2025 Spine Summit, donde el Dr. Nicholas Theodore mostrará la tecnología NOCISCAN de la empresa. NOCISCAN es una plataforma SaaS pionera que combina espectroscopia MR con inteligencia aumentada para ayudar a los médicos a identificar la ubicación del dolor lumbar crónico.
El Dr. Theodore, que es profesor en la Escuela de Medicina de la Universidad Johns Hopkins y ocupa múltiples cargos directivos, presentará 'NOCISCAN, Inteligencia Aumentada y Soporte en la Toma de Decisiones para el Dolor Lumbar' el 21 de febrero de 2025. La tecnología es particularmente significativa dado que aproximadamente 266 millones de personas en todo el mundo sufren de enfermedades degenerativas de la columna vertebral y dolor lumbar.
NOCISCAN es la primera plataforma respaldada por evidencia que ayuda a los médicos a distinguir de manera no invasiva entre discos dolorosos y no dolorosos en la columna lumbar al cuantificar objetivamente los biomarcadores químicos asociados con el dolor discal.
Aclarion (Nasdaq: ACON)은 2025 척추 정상 회담에 참여할 것이라고 발표했으며, 여기서 Nicholas Theodore 박사가 회사의 NOCISCAN 기술을 선보일 예정입니다. NOCISCAN은 만성 요통의 위치를 식별하는 데 도움을 주기 위해 MR 분광법과 증강 지능을 결합한 혁신적인 SaaS 플랫폼입니다.
Theodore 박사는 Johns Hopkins University School of Medicine의 교수로 여러 관리직을 맡고 있으며, 2025년 2월 21일 'NOCISCAN, 증강 지능 및 요통 의사 결정 지원'을 발표할 예정입니다. 이 기술은 전 세계에서 약 2억 6천 6백만 명이 퇴행성 척추 질환과 요통으로 고통받고 있다는 점에서 특히 중요합니다.
NOCISCAN은 의사들이 요추에서 통증이 있는 디스크와 통증이 없는 디스크를 비침습적으로 구분할 수 있도록 돕는 첫 번째 증거 기반 플랫폼으로, 디스크 통증과 관련된 화학 바이오마커를 객관적으로 정량화합니다.
Aclarion (Nasdaq: ACON) a annoncé sa participation au 2025 Spine Summit, où le Dr Nicholas Theodore présentera la technologie NOCISCAN de l'entreprise. NOCISCAN est une plateforme SaaS pionnière qui combine la spectroscopie MR avec l'intelligence augmentée pour aider les médecins à identifier l'emplacement des douleurs lombaires chroniques.
Le Dr Theodore, qui est professeur à la Johns Hopkins University School of Medicine et occupe plusieurs postes de direction, présentera 'NOCISCAN, Intelligence Augmentée et Support à la Décision pour la Douleur Lombaire' le 21 février 2025. Cette technologie est particulièrement significative compte tenu du fait qu'environ 266 millions de personnes dans le monde souffrent de maladies dégénératives de la colonne vertébrale et de douleurs lombaires.
NOCISCAN est la première plateforme soutenue par des preuves qui aide les médecins à distinguer de manière non invasive entre les disques douloureux et non douloureux dans la colonne lombaire en quantifiant objectivement les biomarqueurs chimiques associés à la douleur discale.
Aclarion (Nasdaq: ACON) gab seine Teilnahme am 2025 Spine Summit bekannt, wo Dr. Nicholas Theodore die NOCISCAN-Technologie des Unternehmens präsentieren wird. NOCISCAN ist eine bahnbrechende SaaS-Plattform, die MR-Spektroskopie mit augmentierter Intelligenz kombiniert, um Ärzten zu helfen, den Ort von chronischen Rückenschmerzen zu identifizieren.
Dr. Theodore, der Professor an der Johns Hopkins University School of Medicine ist und mehrere Leitungspositionen innehat, wird am 21. Februar 2025 'NOCISCAN, Augmentierte Intelligenz und Entscheidungsunterstützung bei Rückenschmerzen' präsentieren. Die Technologie ist besonders bedeutend, da weltweit etwa 266 Millionen Menschen an degenerativen Wirbelsäulenerkrankungen und Rückenschmerzen leiden.
NOCISCAN ist die erste evidenzgestützte Plattform, die Ärzten nicht-invasiv hilft, schmerzhafte von schmerzfreien Bandscheiben in der Lendenwirbelsäule zu unterscheiden, indem sie chemische Biomarker, die mit Bandscheibenschmerzen in Verbindung stehen, objektiv quantifiziert.
- First-of-its-kind technology in pain location identification
- Large addressable market with 266 million potential patients worldwide
- Endorsement from prominent medical expert at Johns Hopkins
- None.
- Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI)
- NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain
BROOMFIELD, Colo., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the 2025 Spine Summit.
Renowned orthopedic surgeon Nicholas Theodore, MD, will discuss how NOCISCAN is revolutionizing spine surgery by combining cutting-edge MR Spectroscopy with augmented intelligence. Dr. Theodore is the Donlin M. Long Professor and Professor of Neurosurgery & Orthopaedic Surgery at Johns Hopkins University School of Medicine. He also serves as the Director of the Neurological Spine Program, Director of the Complex Spine Fellowship Program, and Co-Director of the Carnegie Center for Surgical Innovation for Johns Hopkins University.
“Disruptive technologies require strong advocacy from physician luminaries, and the insights provided by Dr. Theodore and the Aclarion KOL team have been valuable as we strive to make NOCISCAN more broadly available,” said Brent Ness, Chief Executive Officer, Aclarion. “We look forward to Dr. Theodore’s presentation at the Spine Summit as he highlights how NOCISCAN empowers physicians to ‘see’ painful discs that are invisible with traditional imaging so they can develop tailored treatment plans for patients with chronic low back pain.”
PRESENTATION DETAILS:
- TITLE: NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support
- PRESENTER: Dr. Nicholas Theodore
- DATE: Friday, February 21, 2025
- TIME: 1:15 PM EST
- LOCATION: JW Marriott Tampa Water Street
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s NOCISCAN solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. NOCISCAN objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain.
For a copy of the NOCISCAN presentation, please email: info@aclarion.com
To find a NOCISCAN center, view our site map here.
This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities of Aclarion, Inc. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
What is NOCISCAN's unique technology advantage for chronic back pain diagnosis?
When will Dr. Theodore present NOCISCAN at the 2025 Spine Summit?
How many people could potentially benefit from Aclarion's NOCISCAN technology?
What makes NOCISCAN different from traditional imaging methods for back pain?
